NASDAQ:MGEN - Miragen Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.86 -0.36 (-4.99 %)
(As of 05/24/2018 04:00 PM ET)
Previous Close$7.22
Today's Range$6.75 - $7.23
52-Week Range$5.01 - $15.91
Volume187,238 shs
Average Volume246,676 shs
Market Capitalization$218.90 million
P/E Ratio-4.93
Dividend YieldN/A
Beta1.32

About Miragen Therapeutics (NASDAQ:MGEN)

Miragen Therapeutics logoMiragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of microRNA-155, which is in Phase I clinical trial for treating cutaneous T-cell lymphoma; MRG-201, a replacement for microRNA-29, which is in Phase I clinical trial that is found at low levels in various pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis; and MRG-110, an inhibitor of microRNA-92 that is expressed in endothelial cells and has shown to accelerate the formation of new blood vessels in preclinical models of heart failure, peripheral ischemia, and dermal wounding in the United States and Japan. The company also develops MRG-107, an inhibitor of miR-155 for treating neuronal amyotrophic lateral sclerosis, and other neurodegenerative indications, including spinal cord injury. It also develops preclinical product candidates for treating various indications, including oncology, visual pathologies, neurodegeneration, and hearing loss. Miragen Therapeutics, Inc. has a collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier for the development of MRG-110. The company was founded in 2006 and is based in Boulder, Colorado.

Receive MGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MGEN
CUSIPN/A
Phone720-643-5200

Debt

Debt-to-Equity Ratio0.14
Current Ratio20.91
Quick Ratio20.91

Price-To-Earnings

Trailing P/E Ratio-4.93
Forward P/E Ratio-6.18
P/E GrowthN/A

Sales & Book Value

Annual Sales$4 million
Price / Sales51.78
Cash FlowN/A
Price / CashN/A
Book Value$2.41 per share
Price / Book2.85

Profitability

EPS (Most Recent Fiscal Year)($1.38)
Net Income$-26,510,000.00
Net Margins-290.61%
Return on Equity-50.53%
Return on Assets-40.91%

Miscellaneous

Employees65
Outstanding Shares30,190,000

Miragen Therapeutics (NASDAQ:MGEN) Frequently Asked Questions

What is Miragen Therapeutics' stock symbol?

Miragen Therapeutics trades on the NASDAQ under the ticker symbol "MGEN."

How were Miragen Therapeutics' earnings last quarter?

Miragen Therapeutics Inc. (NASDAQ:MGEN) released its quarterly earnings data on Wednesday, May, 9th. The medical research company reported ($0.18) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.25) by $0.07. The medical research company had revenue of $4.78 million for the quarter, compared to the consensus estimate of $1.17 million. Miragen Therapeutics had a negative net margin of 290.61% and a negative return on equity of 50.53%. View Miragen Therapeutics' Earnings History.

What price target have analysts set for MGEN?

9 brokers have issued twelve-month target prices for Miragen Therapeutics' shares. Their forecasts range from $13.00 to $29.00. On average, they expect Miragen Therapeutics' stock price to reach $17.1875 in the next year. View Analyst Ratings for Miragen Therapeutics.

What are Wall Street analysts saying about Miragen Therapeutics stock?

Here are some recent quotes from research analysts about Miragen Therapeutics stock:
  • 1. According to Zacks Investment Research, "Miragen Therapeutics, Inc. is a biopharmaceutical company. It develops microRNA biology, oligonucleotide chemistry, drugs and therapies for cancer, pathologic fibrosis, neuro-inflammatory and cardiovascular diseases. Miragen Therapeutics, Inc., formerly known as Signal Genetics, is headquartered in Boulder, Colorado. " (5/16/2018)
  • 2. Cann analysts commented, "MiRagen Therapeutics announced today positive new interim data from its phase I clinical trial of MRG-106 in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL) will be presented on February 2, 2018, at the 10th Annual T-cell Lymphoma Forum in La Jolla, California. These positive results support MiRagen’s plans to initiate a phase II study of MRG-106 in CTCL in the second half of 2018. The data released today, along with the planned phase II trial design support our expectation that MRG-106 will be able to proceed to a registration phase II study, avoiding phase III trials." (2/2/2018)

Who are some of Miragen Therapeutics' key competitors?

Who are Miragen Therapeutics' key executives?

Miragen Therapeutics' management team includes the folowing people:
  • Mr. Bruce L. Booth Ph.D., D.Phil., Co-Founder & Chairman (Age 44)
  • Dr. William Stuart Marshall Ph.D., Co-Founder, Pres, CEO & Director (Age 54)
  • Dr. Eric N. Olson Ph.D., Co-Founder and Member of Scientific Advisory Board
  • Dr. Michael R. Bristow M.D., Ph.D., Co-Founder and Member of the Scientific Advisory Board (Age 73)
  • Dr. Marvin H. Caruthers Ph.D., Co-Founder and Member of Scientific Advisory Board (Age 78)

Has Miragen Therapeutics been receiving favorable news coverage?

News stories about MGEN stock have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Miragen Therapeutics earned a news impact score of 0.06 on Accern's scale. They also gave media headlines about the medical research company an impact score of 46.73 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Miragen Therapeutics' major shareholders?

Miragen Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Opaleye Management Inc. (3.51%), BlackRock Inc. (2.68%), Artal Group S.A. (1.66%), Northern Trust Corp (0.57%), Dimensional Fund Advisors LP (0.54%) and CVI Holdings LLC (0.31%). Company insiders that own Miragen Therapeutics stock include Adam Scott Levy, Bruce Booth, Kyle Lefkoff and Thomas E Hughes. View Institutional Ownership Trends for Miragen Therapeutics.

Which major investors are buying Miragen Therapeutics stock?

MGEN stock was purchased by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Artal Group S.A., BlackRock Inc., Dimensional Fund Advisors LP, CVI Holdings LLC, Millennium Management LLC, Northern Trust Corp and Citadel Advisors LLC. Company insiders that have bought Miragen Therapeutics stock in the last two years include Adam Scott Levy and Bruce Booth. View Insider Buying and Selling for Miragen Therapeutics.

How do I buy shares of Miragen Therapeutics?

Shares of MGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Miragen Therapeutics' stock price today?

One share of MGEN stock can currently be purchased for approximately $6.86.

How big of a company is Miragen Therapeutics?

Miragen Therapeutics has a market capitalization of $218.90 million and generates $4 million in revenue each year. The medical research company earns $-26,510,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Miragen Therapeutics employs 65 workers across the globe.

How can I contact Miragen Therapeutics?

Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 720-643-5200 or via email at [email protected]


MarketBeat Community Rating for Miragen Therapeutics (MGEN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  133 (Vote Outperform)
Underperform Votes:  100 (Vote Underperform)
Total Votes:  233
MarketBeat's community ratings are surveys of what our community members think about Miragen Therapeutics and other stocks. Vote "Outperform" if you believe MGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Miragen Therapeutics (NASDAQ:MGEN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Miragen Therapeutics in the last 12 months. Their average twelve-month price target is $17.1875, suggesting that the stock has a possible upside of 150.55%. The high price target for MGEN is $29.00 and the low price target for MGEN is $13.00. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.892.893.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.1875$17.1875$17.90$23.00
Price Target Upside: 150.55% upside164.42% upside102.26% upside144.16% upside

Miragen Therapeutics (NASDAQ:MGEN) Consensus Price Target History

Price Target History for Miragen Therapeutics (NASDAQ:MGEN)

Miragen Therapeutics (NASDAQ:MGEN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2018WedbushReiterated RatingOutperform$19.00LowView Rating Details
4/9/2018CowenReiterated RatingHoldMediumView Rating Details
3/29/2018Jefferies GroupInitiated CoverageBuy ➝ Buy$14.00MediumView Rating Details
3/22/2018Deutsche BankInitiated CoverageBuy$15.00MediumView Rating Details
3/9/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$19.00LowView Rating Details
2/2/2018CannReiterated RatingBuy$13.00LowView Rating Details
1/16/2018Chardan CapitalReiterated RatingBuyLowView Rating Details
1/12/2018OppenheimerInitiated CoverageOutperform$13.00HighView Rating Details
1/5/2018B. RileyInitiated CoverageBuy ➝ Buy$15.50HighView Rating Details
8/21/2016Rodman & RenshawSet Price TargetBuy$4.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Miragen Therapeutics (NASDAQ:MGEN) Earnings History and Estimates Chart

Earnings by Quarter for Miragen Therapeutics (NASDAQ:MGEN)

Miragen Therapeutics (NASDAQ:MGEN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.13)
2019 EPS Consensus Estimate: ($1.30)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.27)($0.22)($0.25)
Q2 20184($0.30)($0.21)($0.27)
Q3 20183($0.30)($0.30)($0.30)
Q4 20184($0.33)($0.30)($0.32)
Q1 20192($0.34)($0.32)($0.33)
Q2 20192($0.34)($0.31)($0.33)
Q3 20192($0.35)($0.30)($0.33)
Q4 20192($0.35)($0.29)($0.32)

Miragen Therapeutics (NASDAQ MGEN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018Q1 2018($0.2470)($0.18)$1.17 million$4.78 millionViewN/AView Earnings Details
3/14/2018Q4 2017($0.33)($0.29)$1.22 million$1.19 millionViewListenView Earnings Details
11/8/2017Q3 2017($0.3930)($0.27)$0.72 million$1.63 millionViewN/AView Earnings Details
8/11/2017Q2 2017($0.47)($0.34)$0.46 million$0.72 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.24)($0.60)$1.00 million$0.46 millionViewN/AView Earnings Details
3/24/2017Q4 2016($7.72)$0.76 millionViewN/AView Earnings Details
8/15/2016Q2 2016($4.05)($3.45)$1.00 million$0.87 millionViewN/AView Earnings Details
5/16/2016Q116($0.28)($0.26)$645.00 million$808.00 millionViewN/AView Earnings Details
3/16/2016Q415($0.36)($0.28)$0.60 million$0.66 millionViewN/AView Earnings Details
11/12/2015Q3 2015($5.85)$0.50 millionViewN/AView Earnings Details
8/12/2015Q215($0.39)($0.33)$0.73 millionViewN/AView Earnings Details
5/14/2015Q115($0.36)($0.45)$1.90 million$0.65 millionViewN/AView Earnings Details
3/30/2015($0.39)($1.72)ViewN/AView Earnings Details
11/14/2014Q3 2014($0.05)($0.43)$1.30 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Miragen Therapeutics (NASDAQ:MGEN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Miragen Therapeutics (NASDAQ MGEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 18.90%
Institutional Ownership Percentage: 33.15%
Insider Trading History for Miragen Therapeutics (NASDAQ:MGEN)
Institutional Ownership by Quarter for Miragen Therapeutics (NASDAQ:MGEN)

Miragen Therapeutics (NASDAQ MGEN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/13/2018Adam Scott LevyInsiderBuy9,090$5.50$49,995.0010,540View SEC Filing  
2/13/2018Bruce BoothDirectorBuy545,454$5.50$2,999,997.00View SEC Filing  
12/20/2017Thomas E. HughesDirectorSell12,000$8.00$96,000.00View SEC Filing  
6/22/2017Adam Scott LevyInsiderBuy200$7.55$1,510.00200View SEC Filing  
3/10/2017Kyle LefkoffDirectorSell5,800$14.34$83,172.00View SEC Filing  
3/8/2017Kyle LefkoffDirectorSell15,000$15.40$231,000.00View SEC Filing  
2/28/2017Kyle LefkoffDirectorSell10,258$13.89$142,483.62View SEC Filing  
2/23/2017Kyle LefkoffDirectorSell5,902$14.14$83,454.28View SEC Filing  
11/20/2015Samuel D. RiccitelliCEOBuy14,000$0.79$11,060.00345,130View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Miragen Therapeutics (NASDAQ MGEN) News Headlines

Source:
DateHeadline
Q2 2018 Earnings Estimate for Miragen Therapeutics Inc. Issued By Wedbush (MGEN)Q2 2018 Earnings Estimate for Miragen Therapeutics Inc. Issued By Wedbush (MGEN)
www.americanbankingnews.com - May 21 at 1:06 AM
Miragen Therapeutics (MGEN) "Outperform" Rating Reaffirmed at WedbushMiragen Therapeutics' (MGEN) "Outperform" Rating Reaffirmed at Wedbush
www.americanbankingnews.com - May 18 at 4:45 PM
miRagen Therapeutics to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at the 2018 American ...miRagen Therapeutics to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at the 2018 American ...
globenewswire.com - May 18 at 5:04 AM
miRagen Therapeutics (MGEN) to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at ASCOmiRagen Therapeutics (MGEN) to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at ASCO
www.streetinsider.com - May 18 at 5:04 AM
FDA Thumbs-Down Makes EOLS Frown, IMMU Up On Breast Cancer Data, MGEN On WatchFDA Thumbs-Down Makes EOLS Frown, IMMU Up On Breast Cancer Data, MGEN On Watch
www.nasdaq.com - May 17 at 5:31 AM
miRagen Therapeutics to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at the 2018 American Society of Clinical Oncology Annual MeetingmiRagen Therapeutics to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at the 2018 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 17 at 5:31 AM
Miragen Therapeutics (MGEN) Cut to Hold at Zacks Investment ResearchMiragen Therapeutics (MGEN) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - May 16 at 3:24 PM
Veracyte (VCYT) vs. Miragen Therapeutics (MGEN) Head-To-Head AnalysisVeracyte (VCYT) vs. Miragen Therapeutics (MGEN) Head-To-Head Analysis
www.americanbankingnews.com - May 16 at 10:58 AM
Q2 2018 Earnings Forecast for Miragen Therapeutics Inc. (MGEN) Issued By Jefferies GroupQ2 2018 Earnings Forecast for Miragen Therapeutics Inc. (MGEN) Issued By Jefferies Group
www.americanbankingnews.com - May 14 at 2:15 AM
B. Riley Analysts Decrease Earnings Estimates for Miragen Therapeutics Inc. (MGEN)B. Riley Analysts Decrease Earnings Estimates for Miragen Therapeutics Inc. (MGEN)
www.americanbankingnews.com - May 14 at 2:14 AM
Miragen Therapeutics (MGEN) Issues Quarterly  Earnings ResultsMiragen Therapeutics (MGEN) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 11:14 PM
Oppenheimer Comments on Miragen Therapeutics Inc.s Q2 2018 Earnings (MGEN)Oppenheimer Comments on Miragen Therapeutics Inc.'s Q2 2018 Earnings (MGEN)
www.americanbankingnews.com - May 11 at 8:34 AM
$1.17 Million in Sales Expected for Miragen Therapeutics Inc. (MGEN) This Quarter$1.17 Million in Sales Expected for Miragen Therapeutics Inc. (MGEN) This Quarter
www.americanbankingnews.com - May 11 at 3:52 AM
Miragen Therapeutics Inc. (MGEN) Receives Consensus Recommendation of "Buy" from BrokeragesMiragen Therapeutics Inc. (MGEN) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 10 at 3:33 PM
miRagen Therapeutics (MGEN) CEO William Marshall on Q1 2018 Results - Earnings Call TranscriptmiRagen Therapeutics' (MGEN) CEO William Marshall on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 5:01 AM
miRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate UpdatemiRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 10 at 5:01 AM
Should Miragen Therapeutics Inc’s (NASDAQ:MGEN) Recent Earnings Decline Worry You?Should Miragen Therapeutics Inc’s (NASDAQ:MGEN) Recent Earnings Decline Worry You?
finance.yahoo.com - May 9 at 5:09 AM
miRagen Therapeutics Announces New Interim Data From Phase 1 Clinical Trial of Cobomarsen in Mycosis FungoidesmiRagen Therapeutics Announces New Interim Data From Phase 1 Clinical Trial of Cobomarsen in Mycosis Fungoides
finance.yahoo.com - May 9 at 5:09 AM
-$0.26 EPS Expected for Miragen Therapeutics Inc. (MGEN) This Quarter-$0.26 EPS Expected for Miragen Therapeutics Inc. (MGEN) This Quarter
www.americanbankingnews.com - May 9 at 3:12 AM
Enzo Biochem (ENZ) vs. Miragen Therapeutics (MGEN) Financial ContrastEnzo Biochem (ENZ) vs. Miragen Therapeutics (MGEN) Financial Contrast
www.americanbankingnews.com - May 5 at 3:13 AM
miRagen Therapeutics (MGEN) Reports Initiation of Second Phase 1 Clinical Trial of MRG-110miRagen Therapeutics (MGEN) Reports Initiation of Second Phase 1 Clinical Trial of MRG-110
www.streetinsider.com - May 4 at 3:13 PM
miRagen Therapeutics to Report First Quarter 2018 Financial Results and Host Conference Call on May 9, 2018miRagen Therapeutics to Report First Quarter 2018 Financial Results and Host Conference Call on May 9, 2018
finance.yahoo.com - May 2 at 3:10 PM
Second early-stage study of miRagens MRG-110 on goSecond early-stage study of miRagen's MRG-110 on go
seekingalpha.com - May 1 at 3:02 PM
miRagen Therapeutics Announces Initiation of Second Phase 1 Clinical Trial of MRG-110miRagen Therapeutics Announces Initiation of Second Phase 1 Clinical Trial of MRG-110
finance.yahoo.com - May 1 at 3:01 PM
Miragen Therapeutics (MGEN) Stock Rating Reaffirmed by WedbushMiragen Therapeutics (MGEN) Stock Rating Reaffirmed by Wedbush
www.americanbankingnews.com - April 30 at 4:12 PM
Comparing Miragen Therapeutics (MGEN) & Genomic Health (GHDX)Comparing Miragen Therapeutics (MGEN) & Genomic Health (GHDX)
www.americanbankingnews.com - April 28 at 7:26 AM
miRagen Therapeutics Announces New Data Showing Administration of MRG-110 Improved Tissue PerfusionmiRagen Therapeutics Announces New Data Showing Administration of MRG-110 Improved Tissue Perfusion
www.nasdaq.com - April 27 at 3:02 PM
miRagen Therapeutics (MGEN) Say Data Shows Administration of MRG-110 Improved Tissue Perfusion and Wound Healing in Late Stage Preclinical StudiesmiRagen Therapeutics (MGEN) Say Data Shows Administration of MRG-110 Improved Tissue Perfusion and Wound Healing in Late Stage Preclinical Studies
www.streetinsider.com - April 27 at 3:02 PM
miRagen Therapeutics Announces New Data Showing Administration of MRG-110 Improved Tissue Perfusion and Wound Healing in Late Stage Preclinical StudiesmiRagen Therapeutics Announces New Data Showing Administration of MRG-110 Improved Tissue Perfusion and Wound Healing in Late Stage Preclinical Studies
finance.yahoo.com - April 27 at 3:02 PM
Miragen Therapeutics (MGEN) & Its Rivals Head to Head ComparisonMiragen Therapeutics (MGEN) & Its Rivals Head to Head Comparison
www.americanbankingnews.com - April 27 at 10:08 AM
miRagen Therapeutics to Present New Preclinical Data at the Wound Healing Society and the Association for Research in Vision and Ophthalmology Annual MeetingsmiRagen Therapeutics to Present New Preclinical Data at the Wound Healing Society and the Association for Research in Vision and Ophthalmology Annual Meetings
finance.yahoo.com - April 27 at 5:11 AM
 Brokerages Expect Miragen Therapeutics Inc. (MGEN) to Announce -$0.26 EPS Brokerages Expect Miragen Therapeutics Inc. (MGEN) to Announce -$0.26 EPS
www.americanbankingnews.com - April 21 at 9:06 PM
Miragen Therapeutics (MGEN) Rating Lowered to Hold at Zacks Investment ResearchMiragen Therapeutics (MGEN) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 21 at 7:24 AM
Miragen Therapeutics (MGEN) Upgraded to "Hold" at ValuEngineMiragen Therapeutics (MGEN) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - April 20 at 1:19 PM
Miragen Therapeutics (MGEN) Raised to Buy at Zacks Investment ResearchMiragen Therapeutics (MGEN) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - April 18 at 9:00 AM
Miragen Therapeutics (MGEN) Stock Rating Reaffirmed by Chardan CapitalMiragen Therapeutics (MGEN) Stock Rating Reaffirmed by Chardan Capital
www.americanbankingnews.com - April 16 at 12:02 PM
Head-To-Head Analysis: Miragen Therapeutics (MGEN) vs. The CompetitionHead-To-Head Analysis: Miragen Therapeutics (MGEN) vs. The Competition
www.americanbankingnews.com - April 15 at 11:14 PM
Miragen Therapeutics Inc. (MGEN) Given Average Recommendation of "Buy" by AnalystsMiragen Therapeutics Inc. (MGEN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 15 at 9:57 AM
Head to Head Comparison: Miragen Therapeutics (MGEN) versus Its RivalsHead to Head Comparison: Miragen Therapeutics (MGEN) versus Its Rivals
www.americanbankingnews.com - April 12 at 9:51 AM
Financial Review: Miragen Therapeutics (MGEN) vs. Its CompetitorsFinancial Review: Miragen Therapeutics (MGEN) vs. Its Competitors
www.americanbankingnews.com - April 12 at 1:15 AM
Miragen Therapeutics (MGEN) Rating Reiterated by Chardan CapitalMiragen Therapeutics (MGEN) Rating Reiterated by Chardan Capital
www.americanbankingnews.com - April 10 at 5:03 PM
Miragen Therapeutics (MGEN) Stock Rating Upgraded by Zacks Investment ResearchMiragen Therapeutics (MGEN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 10 at 9:44 AM
Miragen Therapeutics (MGEN) "Hold" Rating Reiterated at CowenMiragen Therapeutics' (MGEN) "Hold" Rating Reiterated at Cowen
www.americanbankingnews.com - April 9 at 6:02 AM
Form 8-K MIRAGEN THERAPEUTICS, For: Apr 03Form 8-K MIRAGEN THERAPEUTICS, For: Apr 03
www.streetinsider.com - April 8 at 3:10 PM
Financial Survey: Miragen Therapeutics (MGEN) and Its RivalsFinancial Survey: Miragen Therapeutics (MGEN) and Its Rivals
www.americanbankingnews.com - April 7 at 1:26 PM
 Brokerages Anticipate Miragen Therapeutics, Inc. (MGEN) Will Post Quarterly Sales of $1.17 Million Brokerages Anticipate Miragen Therapeutics, Inc. (MGEN) Will Post Quarterly Sales of $1.17 Million
www.americanbankingnews.com - April 6 at 1:56 AM
Miragen Therapeutics (MGEN) Downgraded to Hold at Zacks Investment ResearchMiragen Therapeutics (MGEN) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 5 at 11:52 PM
Miragen Therapeutics (MGEN) vs. Its Peers Head-To-Head ContrastMiragen Therapeutics (MGEN) vs. Its Peers Head-To-Head Contrast
www.americanbankingnews.com - April 5 at 3:08 AM
-$0.26 EPS Expected for Miragen Therapeutics, Inc. (MGEN) This Quarter-$0.26 EPS Expected for Miragen Therapeutics, Inc. (MGEN) This Quarter
www.americanbankingnews.com - April 4 at 11:10 PM
Miragen Therapeutics, Inc. (MGEN) to Post Q1 2018 Earnings of ($0.27) Per Share, B. Riley ForecastsMiragen Therapeutics, Inc. (MGEN) to Post Q1 2018 Earnings of ($0.27) Per Share, B. Riley Forecasts
www.americanbankingnews.com - March 30 at 6:52 AM

SEC Filings

Miragen Therapeutics (NASDAQ:MGEN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Miragen Therapeutics (NASDAQ:MGEN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Miragen Therapeutics (NASDAQ MGEN) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.